KR100895324B1 - 성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 - Google Patents
성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 Download PDFInfo
- Publication number
- KR100895324B1 KR100895324B1 KR1020070044663A KR20070044663A KR100895324B1 KR 100895324 B1 KR100895324 B1 KR 100895324B1 KR 1020070044663 A KR1020070044663 A KR 1020070044663A KR 20070044663 A KR20070044663 A KR 20070044663A KR 100895324 B1 KR100895324 B1 KR 100895324B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- insulin
- stem cells
- differentiation
- peptide
- Prior art date
Links
- 210000002660 insulin-secreting cell Anatomy 0.000 title claims abstract description 75
- 230000004069 differentiation Effects 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 30
- 210000004504 adult stem cell Anatomy 0.000 title claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 142
- 239000008103 glucose Substances 0.000 claims abstract description 61
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 60
- 239000001963 growth medium Substances 0.000 claims abstract description 54
- 108010023082 activin A Proteins 0.000 claims abstract description 41
- 210000004003 subcutaneous fat Anatomy 0.000 claims abstract description 29
- 238000000338 in vitro Methods 0.000 claims abstract description 22
- 206010033675 panniculitis Diseases 0.000 claims abstract description 20
- 230000001815 facial effect Effects 0.000 claims abstract description 16
- 102000004127 Cytokines Human genes 0.000 claims abstract description 14
- 108090000695 Cytokines Proteins 0.000 claims abstract description 14
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims abstract description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 5
- 102100040918 Pro-glucagon Human genes 0.000 claims abstract description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 54
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims description 43
- 229960003966 nicotinamide Drugs 0.000 claims description 27
- 235000005152 nicotinamide Nutrition 0.000 claims description 27
- 239000011570 nicotinamide Substances 0.000 claims description 27
- 210000001519 tissue Anatomy 0.000 claims description 20
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 13
- 230000006698 induction Effects 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 239000007758 minimum essential medium Substances 0.000 claims description 4
- 239000007757 Media 199 Substances 0.000 claims description 2
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000006481 glucose medium Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 abstract description 67
- 210000001691 amnion Anatomy 0.000 abstract description 13
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 10
- 230000001939 inductive effect Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- -1 Activin A Chemical compound 0.000 abstract description 3
- 238000004113 cell culture Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 87
- 108090001061 Insulin Proteins 0.000 description 45
- 102000004877 Insulin Human genes 0.000 description 45
- 229940125396 insulin Drugs 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 43
- 206010012601 diabetes mellitus Diseases 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 36
- 239000008280 blood Substances 0.000 description 36
- 241000700159 Rattus Species 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 26
- 108010075254 C-Peptide Proteins 0.000 description 25
- 238000007920 subcutaneous administration Methods 0.000 description 22
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 19
- 238000003127 radioimmunoassay Methods 0.000 description 17
- 238000003757 reverse transcription PCR Methods 0.000 description 17
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 8
- 108010066302 Keratin-19 Proteins 0.000 description 8
- 108010076181 Proinsulin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000012760 immunocytochemical staining Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 210000002370 ICC Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 238000010988 intraclass correlation coefficient Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010059616 Activins Proteins 0.000 description 5
- 102000005606 Activins Human genes 0.000 description 5
- 102000030595 Glucokinase Human genes 0.000 description 5
- 108010021582 Glucokinase Proteins 0.000 description 5
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 5
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 5
- 108010066327 Keratin-18 Proteins 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007446 glucose tolerance test Methods 0.000 description 5
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 4
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 4
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102100038553 Neurogenin-3 Human genes 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000604 fetal stem cell Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 101150070110 Isl1 gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150111723 PDX1 gene Proteins 0.000 description 2
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 2
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004190 ion pair chromatography Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101710173678 Glucagon-5 Proteins 0.000 description 1
- 101150068639 Hnf4a gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000011795 OF1 mouse Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000003425 amniotic epithelial cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000015031 pancreas development Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
- C12N2506/025—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells from extra-embryonic cells, e.g. trophoblast, placenta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
세포 종류 | 배양액 내 인슐린 첨가여부 | 분석방법 | 인슐린 분석 | 참고문헌 |
태아 간 유래 전구세포 | + | RT-PCR ELISA | 5 ng/106 cells | Zalzman et al., 2003 1) |
췌장 유래 세포 | + | RT-PCR ELISA | 16 ng/2x105 cells | Gao et al., 2003 2) |
간 유래 전구세포 | + | RT-PCR RIA ICC | 0.25 pmol/ug DNA | Nakajima-Nagata et al., 2004 3) |
신경전구세포 | + | RT-PCR ICC RIA | 2 ng/ml/50 IPCs | Hori et al., 2005 4) |
췌장 유래 세포 | - | RT-PCR ICC | Zhao et al., 2005 5) | |
췌장섬 유래 중간엽 줄기세포 | - | ICC IHC | Eberhardt et al., 2006 6) | |
지방 유래 중간엽 줄기세포 | - | RT-PCR ICC | Timber et al., 2006 7) | |
태아 췌장 세포 | - | RIA | 3.6 pg/mg DNA | Otonkoski et al., 1993 8) |
췌장섬 유래 전구세포 | - | RT-PCR ICC RIA | 220 pg/ml | Abraham, 2002 9) |
말초혈액 유래 단핵세포 | - | RIA | 120 pg/mg protein | Ruhnke et al. 2005 10) |
RT-PCR, reverse transcription-polymerase chain reaction, 역전사-중합효소 연쇄 반응; ICC, immunocytochemistry, 면역세포화학염색법; IHC, immunohistochemistry, 면역조직화학염색법; RIA, radioimmuno assay, 방사면역측정법. |
세포 종류 | 분화 검증 | 세포 이식 방법 | 생체 검사 | 참고문헌 |
태아 췌장 세포 | 미분화 | NOD-SCID mice, 2000 cell aggregates, IP 이식 70일 간 관찰 | 혈당측정 | Wu et al., 2004 1) |
제대혈 유래 단핵세포 | 미분화 | NOD mice, 1x107 cells IP 이식 | IHC | Yosida et al., 2005 2) |
말초혈액 단핵세포 | RIA | OF1 mice, 5x106 cells 신장캡슐 이식 10일 후 검사 | IHC | Ruhnke et al., 2005 3) |
췌장유래 세포 | RT-PCR IHC | SCID mice, 2.5x106 cells 신장캡슐이식 7일~43일 간 관찰 | 혈당측정 GTT IHC | Zhao et al., 2005 4) |
태아 췌장 세포 | IHC RIA RT-PCR | Nude BALB/C mice, 500 ICCs 신장캡슐이식 3달 후 검사 | 혈당측정 GTT ELISA (씨-펩타이드) | Otonkoski et al., 1993 5) |
신경전구 세포 | RT-PCR IHC RIA | NOD-SCID mice, 500 IPCs 신장캡슐이식 4주 후 관찰 | GTT ELISA (씨-펩타이드) IHC | Hori et al., 2005 6) |
RT-PCR, reverse transcription-polymerase chain reaction, 역전사-중합효소 연쇄 반응; ICC, immunocytochemistry, 면역세포화학염색법; IHC, immunohistochemistry, 면역조직화학염색법; RIA, radioimmuno assay, 방사면역측정법; GTT, glucose tolerance test, 당부하검사; ELISA, enzyme-linked immunosorbent assay, 효소면역측정법. |
유전자 | 프라이머(서열번호) | 크기 (bp) | 풀림 온도(℃) | Reference |
GAPDH | 5'- aca act ttg gta tcg tgg aa -3' (1) 5'- aaa ttc gtt gtc ata cca gg -3' (2) | 456 | 53 | NM_002046 |
insulin | 5'- aac caa cac ctg tgc ggc tc -3' (3) 5'- aag ggc ttt att cca tct ctc tcg -3' (4) | 320 | 59 | J00265 |
ngn3 | 5'- cgt gaa ctc ctt gaa ctg agc ag -3' (5) 5'- tgg cac tcc tgg gac gag ttt c -3' (6) | 211 | 61 | AF234829 |
pdx1 | 5'- ccc atg gat gaa gtc tac g -3' (7) 5'- gtc ctc ctc ctt ttt cca c -3' (8) | 262 | 54 | NM_000209 |
Glucokinase | 5'- gaa tac ccc cca gag acc ttt tc -3' (9) 5'- ggt ttc ttcc tga gcc agc g -3' (10) | 182 | 61 | M90299 |
Isl1 | 5'- agc atc aat gtc ctc tca act tcc -3' (11) 5'- tgt ttg gca agg caa tga cc -3' (12) | 493 | 57 | NM_002202 |
Nkx6.1 | 5'- aca cga gac cca ctt ttt ccg -3' (13) 5'- tgc tgg act tgt gctt ctt caa c -3' (14) | 336 | 59 | NM_006168 |
Glut 2 | 5'- agc ttt gca gtt ggt gga at -3' (15) 5'- aat aag aat gcc cgt gac ga -3' (16) | 300 | 57 | NM_000340 |
Beta 2 | 5'- cag aac cag gac atg ccc -3' (17) 5'- atc aaa gga agg gct ggt g -3' (18) | 216 | 60 | NM_002500 |
Glucagon | 5'- atg aac gag gac aag cgc -3' (19) 5'- gta acg aac cga cca ctt -3' (20) | 236 | 57 | NM_002054 |
CK18 | 5'- gag atc gag gct ctc aag ga -3' (21) 5'- caa gct ggc ctt cag att tc -3' (22) | 357 | 57 | NM_00024 |
HNF4a | 5'- gag cag gaa tgg gaa gaa tg -3' (23) 5'- ggc tgt cct ttg gga tga ag -3'(24) | 205 | 62 | NM_178849 |
Claims (5)
- 인간의 성체 줄기세포를 체외에서 인슐린 분비세포로 분화를 유도 시,20 ~ 30 mM의 고농도 포도당 배양액에 니코티나마이드(nicotinamide), 액티빈 에이(activin A) 및 글루카곤 유사 펩타이드(glucagon-like peptide 1) 중에서 선택된 2종 이상의 싸이토카인을 첨가하여 5 ~ 10일 동안 세포를 배양한 후,4 ~ 7 mM의 저농도 포도당 배양액에 니코티나마이드(nicotinamide), 액티빈 에이(activin A) 및 글루카곤 유사 펩타이드(glucagon-like peptide 1) 중에서 선택된 2종 이상의 싸이토카인을 첨가하여 10 ~ 20일 동안 세포를 배양하는 것을 특징으로 하는 인슐린 분비세포로의 분화 유도방법.
- 제 1 항에 있어서, 상기 성체 줄기세포는 안면 피하 지방조직 또는 양막 조직으로부터 분리된 것임을 특징으로 하는 유도방법.
- 제 1 항에 있어서, 상기 배양액은 디엠이엠(Dulbecco's modified Eagle's medium, DMEM), 아이엠디엠(Iscove's modified Dulbecco's media, IMDM), 알피엠아이1640(RPMI1640), 알파엠이엠(a-Minimum essential media, a-MEM), 햄 에프12 (HAM's F12) 및 199 배양액(Media 199) 중에서 선택된 1종 또는 2종 이상인 것을 특징으로 하는 방법.
- 삭제
- 제 1 항에 있어서, 상기 니코티나마이드는 5 ~ 20 mM, 글루카곤 유사 펩타이드는 5 ~ 20 nM, 액티빈 에이는 1 ~ 10 nM의 농도로 사용하는 것을 특징으로 하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070044663A KR100895324B1 (ko) | 2007-05-08 | 2007-05-08 | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070044663A KR100895324B1 (ko) | 2007-05-08 | 2007-05-08 | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080099052A KR20080099052A (ko) | 2008-11-12 |
KR100895324B1 true KR100895324B1 (ko) | 2009-05-07 |
Family
ID=40286254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070044663A KR100895324B1 (ko) | 2007-05-08 | 2007-05-08 | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100895324B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101334800B1 (ko) * | 2011-02-18 | 2013-12-02 | 주식회사 강스템홀딩스 | 성체 줄기세포로부터 췌장 베타 유사세포를 제조하는 방법 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101025880B1 (ko) * | 2008-10-23 | 2011-03-30 | 공희숙 | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157325A1 (en) | 2002-10-18 | 2004-08-12 | Petersen Bryon E. | Bone marrow cell differentiation |
KR100679642B1 (ko) * | 2005-11-16 | 2007-02-06 | 주식회사 알앤엘바이오 | 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제 |
-
2007
- 2007-05-08 KR KR1020070044663A patent/KR100895324B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157325A1 (en) | 2002-10-18 | 2004-08-12 | Petersen Bryon E. | Bone marrow cell differentiation |
KR100679642B1 (ko) * | 2005-11-16 | 2007-02-06 | 주식회사 알앤엘바이오 | 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제 |
Non-Patent Citations (2)
Title |
---|
Diabetes, Vol.52, pp.1163-1168. |
Science, Vol.292, pp.1389-1394. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101334800B1 (ko) * | 2011-02-18 | 2013-12-02 | 주식회사 강스템홀딩스 | 성체 줄기세포로부터 췌장 베타 유사세포를 제조하는 방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20080099052A (ko) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU776514B2 (en) | Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof | |
KR101089591B1 (ko) | 인간 배아 줄기세포 유래의 섬세포 | |
US20040259244A1 (en) | Methods, compositions, and growth and differentiation factors for insulin-producing cells | |
EP2009095A1 (en) | Method of generating glucose-responsive cells | |
CZ2004696A3 (cs) | Endokrinní pankreatická diferenciace buněk stromatu odvozených z adipózní tkáně a její použití | |
JP5785287B2 (ja) | 脂肪組織由来細胞の調製方法 | |
JP2005503759A (ja) | 幹細胞の膵臓内分泌細胞への分化方法 | |
US7029915B2 (en) | Method for differentiating rat hepatic stem cells to insulin-producing cells | |
US10941384B2 (en) | Compositions and methods for promoting the generation of endocrine cells | |
JP2021054869A (ja) | 膵島移植のための改善された方法 | |
KR101025880B1 (ko) | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법 | |
JP2018507889A (ja) | 肥満及び2型糖尿病(t2d)の治療のための膵内分泌前駆細胞療法 | |
KR100895324B1 (ko) | 성체 줄기세포를 이용한 인슐린 분비세포로의 분화유도방법 | |
KR20210024557A (ko) | 인슐린 생산용 소도 세포를 확산시키기 위한 조성물 및 방법 및 이의 치료적 용도 | |
Bouckenooghe et al. | Modulation of specific beta cell gene (re) expression during in vitro expansion of human pancreatic islet cells | |
RU2430158C1 (ru) | Способ дифференцировки стволовых клеток взрослого человека в клетки, секретирующие инсулин | |
KR101491108B1 (ko) | 피부세포로부터 기능성 인슐린 생산 세포의 직접 제조방법 | |
Racanicchi et al. | Neonatal Pig Liver–Derived Progenitors for Insulin-Producing Cells: An In Vitro Study | |
Collier et al. | Pancreatic Islet Beta-Cell Replacement Strategies | |
IL214601A (en) | A method for increasing the pool of endocrine + 3ngn progenitor cells and pancreatic endocrine mass | |
AU2010201431A1 (en) | Method for the differentiation of human adult stem cells into insulin-secreting cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130206 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140404 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151021 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161021 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170510 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180205 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190130 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200303 Year of fee payment: 12 |
|
R401 | Registration of restoration |